Granted Patent
B2
US 12,295,985 · App. 18/073,951 · Granted May 13, 2025
Methods of reducing severity of glaucoma by intravitreal administration of insulin-like growth factor binding protein-like 1 (IGFBPL1)
A61K38/18A61K31/00A61K31/352A61K31/7004A61K31/708A61K31/7088A61K31/7105A61K31/711A61K31/713A61K38/1738A61K38/1841A61K38/2278A61K38/30A61K45/06A61K9/0019A61K9/0048A61K9/0085A61K9/5169A61K35/30A61K38/1703A61K38/1709A61K38/22A61K48/00A61K49/0056A61K2300/00C12N5/0621C12N5/0623C12N2501/105C12N2502/08C12N2502/081C12N2533/50G01N33/5058G01N33/5073Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed is a method of promoting neuronal growth by administering IGFBPL-1, or an agent that increases or stabilizes IGFBPL-1 activity to a subject in need thereof, e.g., a subject in need of treating optic nerve degeneration.
Claims (12)
1. A method of reducing severity of glaucoma in a subject in need thereof, the method comprising intravitreally administering to the subject a composition comprising an insulin-like growth factor binding protein-like 1 (IGFBPL-1) protein.
2. The method of claim 1 , wherein the IGFBPL-1 protein comprises the amino acid sequence of SEQ ID NO: 2.
3. The method of claim 1 , wherein the composition promotes outgrowth of a neuron.
4. The method of claim 3 , wherein the neuron is an optic nerve neuron, a retinal ganglion cell, or a retinal neuron.
5. The method of claim 1 , wherein the glaucoma is angle-closure glaucoma, open-angle glaucoma, secondary glaucoma or congenital glaucoma.
6. The method of claim 1 , wherein reducing severity comprises improving the subject's vision.
7. A method of reducing severity of a neuronal injury in a subject in need thereof, the method comprising intravitreally administering to the subject a composition comprising an IGFBPL-1 protein, wherein the subject has glaucoma.
8. The method of claim 7 , wherein the IGFBPL-1 protein comprises the amino acid sequence of SEQ ID NO: 2.
9. The method of claim 7 , wherein the composition promotes outgrowth of a neuron.
10. The method of claim 9 , wherein the neuron is an optic nerve neuron, a retinal ganglion cell, or a retinal neuron.
11. The method of claim 7 , wherein the glaucoma is angle-closure glaucoma, open-angle glaucoma, secondary glaucoma or congenital glaucoma.
12. The method of claim 7 , wherein reducing severity comprises improving the subject's vision.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 1, 2023
From: CHEN, DONG FENG; GUO, CHENYING
To: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
Reel/Frame 062563/0976 →
Continuity (4)
Continuation
14002033
Provisional Application
61447314
· Feb 28, 2011
References Cited (185)
US 4522811A
· Eppstein et al.
· 1985
[cited by applicant]
US 4816397A
· Boss et al.
· 1989
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4883666A
· Sabel et al.
· 1989
[cited by applicant]
US 4975369A
· Beavers et al.
· 1990
[cited by applicant]
US 4978745A
· Schoemaker et al.
· 1990
[cited by applicant]
US 5443505A
· Wong et al.
· 1995
[cited by applicant]
US 5455044A
· Kim et al.
· 1995
[cited by applicant]
US 5576018A
· Kim et al.
· 1996
[cited by applicant]
US 5766242A
· Wong et al.
· 1998
[cited by applicant]
US 6071889A
· Weiss et al.
· 2000
[cited by applicant]
US 6251090B1
· Avery et al.
· 2001
[cited by applicant]
US 6299895B1
· Hammang et al.
· 2001
[cited by applicant]
US 6375972B1
· Guo et al.
· 2002
[cited by applicant]
US 6413540B1
· Yaacobi
· 2002
[cited by applicant]
US 6416777B1
· Yaacobi
· 2002
[cited by applicant]
US 6468798B1
· Debs et al.
· 2002
[cited by applicant]
US 6596296B1
· Nelson et al.
· 2003
[cited by applicant]
US 7109030B2
· Dedera et al.
· 2006
[cited by applicant]
US 7232880B2
· Oh et al.
· 2007
[cited by applicant]
US 7238529B2
· Benowitz et al.
· 2007
[cited by applicant]
US 7514532B2
· Oh et al.
· 2009
[cited by applicant]
US 7585497B2
· Oh et al.
· 2009
[cited by applicant]
US 7714102B2
· Oh et al.
· 2010
[cited by applicant]
US 7780949B2
· Riser
· 2010
[cited by applicant]
US 8198284B2
· Shie et al.
· 2012
[cited by applicant]
US 8470295B2
· Warren et al.
· 2013
[cited by applicant]
US 20030017513A1
· Khosravi et al.
· 2003
[cited by applicant]
US 20040067882A1
· Alsobrook et al.
· 2004
[cited by applicant]
US 20060276394A1
· Aston et al.
· 2006
[cited by applicant]
US 20080193446A1
· Phillips
· 2008
[cited by applicant]
US 20090156496A1
· Benowitz et al.
· 2009
[cited by applicant]
US 20100120143A1
· Oh et al.
· 2010
[cited by applicant]
US 20120156216A1
· Oh
· 2012
[cited by applicant]
US 20140005098A1
· Godeau et al.
· 2014
[cited by applicant]
US 20140286906A1
· Bilbao Cortes et al.
· 2014
[cited by applicant]
US 20220143139A1
· Chen et al.
· 2022
[cited by applicant]
JP 2013529292
· 2013
[cited by applicant]
WO WO1994023697
· 1994
[cited by applicant]
WO WO1995013796
· 1995
[cited by applicant]
WO WO1997003652
· 1997
[cited by applicant]
WO WO2000040089
· 2000
[cited by applicant]
WO WO2001002847
· 2001
[cited by applicant]
WO WO2002089767
· 2002
[cited by applicant]
WO WO2003040330
· 2003
[cited by applicant]
WO WO2003041655
· 2003
[cited by applicant]
WO WO2004073551
· 2004
[cited by applicant]
WO WO2005005635
· 2005
[cited by applicant]
WO WO2005048914
· 2005
[cited by applicant]
WO WO2007014323
· 2007
[cited by applicant]
WO WO2012118796
· 2012
[cited by applicant]
WO WO2012118863
· 2012
[cited by applicant]
WO WO2017213504
· 2017
[cited by applicant]
WO WO2022256331
· 2022
[cited by applicant]
Burgess et al. J of Cell Bio. 1990, 111:2129-2138.
[cited by examiner]
Bowie et al. Science, 1990, 247:1306-1310.
[cited by examiner]
Pawson et al. 2003, Science 300:445-452.
[cited by examiner]
Alaoui-Ismaili et al., Cytokine Growth Factor Rev. 2009; 20:501-507.
[cited by examiner]
Guo et al., PNAS 2004; 101:9205-9210.
[cited by examiner]
Abbs et al., “Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines,” Ther. Immunol., Dec. 1994, 1(6):325-31.
[cited by applicant]
Adeluyi et al., “Microglia morphology and proinflammatory signaling in the nucleus accumbens during nicotine withdrawal,” Science Advances, Oct. 2019, 5(10):eaax7031, 11 pages.
[cited by applicant]
Benjamini and Hochberg, “Controlling the false discovery rate: a practical and powerful approach to multiple testing,” Journal of the Royal statistical society: series B (Methodological), 1995, 57(1):289-300.
[cited by applicant]
Bolstad et al., “A comparison of normalization methods for high density oligonucleotide array data based on variance and bias,” Bioinformatics, Jan. 2003, 19(2):185-93.
[cited by applicant]
Bourges et al., “Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles,” Invest Opth Vis Sci., Aug. 2003, 44:3562-9.
[cited by applicant]
Butovsky and Weiner, “Microglial signatures and their role in health and disease,” HHS Public Access Author Manuscript, doi: 10.1038/s41583-018-0057-5, published online May 28, 2020, published in final edited form as: N…
[cited by applicant]
Chen et al., “Optic neuropathy due to microbead-induced elevated intraocular pressure in the mouse,” Invest Ophthalmol Vis Sci., Jan. 2011, 52(1):36-44.
[cited by applicant]
Chesler et al., “Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modulate nervous system function,” Nature Genetics, Feb. 2005, 37(3):233-242.
[cited by applicant]
Cianciulli et al., “Microglia Mediated Neuroinflammation: Focus on PBK Modulation,” Biomolecules, Jan. 2020, 10(1):137, 19 pages.
[cited by applicant]
Colcher et al., “Single-Chain Antibodies in Pancreatic Cancer,” Ann. N. Y. Acad. Sci., Jun. 1999, 880(1):263-80.
[cited by applicant]
Colonna and Butovsky, “Microglia Function in the Central Nervous System During Health and Neurodegeneration,” Annu Rev Immunol., Apr. 2017, 35:441-468.
[cited by applicant]
Freeman et al., “Genetic networks in the mouse retina: growth associated protein 43 and phosphatase tensin homolog network,” Mol Vis., May 2011, 17:1355-1372.
[cited by applicant]
Geisert et al., “Gene expression in the mouse eye: an online resource for genetics using 103 strains of mice,” Mol Vis., Aug. 2009, 15:1730-1763.
[cited by applicant]
Hammond et al., “Immune Signaling in Neurodegeneration,” Immunity, Apr. 2019, 50(4):955-974.
[cited by applicant]
Homayouni et al., “Gene clustering by latent semantic indexing of MEDLINE abstracts,” Bioinformatics, Jan. 2005, 21(1):104-15.
[cited by applicant]
Huang et al., “Placental growth factor negatively regulates retinal endothelial cell barrier function through suppression of glucose-6-phosphate dehydrogenase and antioxidant defense systems,” FASEB Journal, Dec. 2019, …
[cited by applicant]
Huang et al., “The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists,” Genome Biology, Sep. 2007, 8:R183, 16 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2022/031615, mailed Dec. 14, 2023, 7 pages.
[cited by applicant]
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, 1986, 321(6069):522-5.
[cited by applicant]
Jung et al., “Analysis of fractalkine receptor CX
[cited by applicant]
Kim and Kim, “Anti-breast cancer activity of Fine Black ginseng (Panax ginseng Meyer) and ginsenoside Rg5,” J Ginseng Res., Apr. 2015, 39(2):125-34.
[cited by applicant]
Li and Barres, “Microglia and macrophages in brain homeostasis and disease,” Nat Rev Immunol., Apr. 2018, 18(4):225-242.
[cited by applicant]
Lian et al., “Protocol for Primary Microglial Culture Preparation,” Bio Protoc., Nov. 2016, 6(21):e1989, 8 pages.
[cited by applicant]
Liao et al., “featureCounts: an efficient general purpose program for assigning sequence reads to genomic features,” Bioinformatics, Apr. 2014, 30(7):923-30.
[cited by applicant]
Liddelow et al., “Neurotoxic Reactive Astrocytes are Induced by Activated Microglia,” Nature, 2017, 541(7638):481-487, 25 pages.
[cited by applicant]
Love et al., “Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2,” Genome Biol., 2014, 15(12):550, 21 pages.
[cited by applicant]
Magni et al., “Parthenolide inhibits the LPS-induced secretion of IL-6 and TNF-α and NF-κB nuclear translocation in BV-2 microglia,” Phytotherapy Research., Sep. 2012, 26(9):1405-1409, 5 pages.
[cited by applicant]
Morrison and Oi, “Genetically Engineered Antibody Molecules,” Adv. Immunol., 1989, 44:65-92.
[cited by applicant]
Morrison et al., “Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains,” Proc. Natl. Acad. Sci., USA, Nov. 1984, 81(21):6801-5.
[cited by applicant]
Ngolab et al., “Reflections on the Utility of 30 the Retina as a Biomarker for Alzheimer's Disease: A Literature Review,” Neurology and Therapy, Dec. 2019, 8(Suppl 2):57-72.
[cited by applicant]
Nishimura et al., “Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen,” Cancer Research, Feb. 1987, 47(4):999-1005.
[cited by applicant]
Normando et al., “The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain,” Acta Neuropatholo…
[cited by applicant]
Padlan, “Anatomy of the antibody molecule,” Molec. Immun., Feb. 1994, 31(3):169-217.
[cited by applicant]
Pan et al., “IGFBPL 1 is a master driver of microglia homeostasis and resolution of neuroinflammation in glaucoma and brain tauopathy,” Cell Rep., Aug. 2023, 42(8):112889, 29 pages.
[cited by applicant]
Pickett et al., “Amyloid beta and tau cooperate to cause reversible behavioral and transcriptional deficits in a model of Alzheimer's disease,” Cell Rep., Dec. 2019, 29(11):3592-3604.e5.
[cited by applicant]
Plóciennik et al., “Activated caspase-3 and neurodegeneration and synaptic plasticity in Alzheimer's disease,” Advances in Alzheimer's Disease, Jan. 2015, 4(3):63-77.
[cited by applicant]
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” Proc. Natl. Acad. Sci. USA, Dec. 1989, 86(24):10029-33.
[cited by applicant]
Reiter and Pastan, “Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins,” Clin. Cancer Res., Feb. 1996, 2(2):245-52.
[cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy,” Nature, Mar. 1988, 332(6162):323-7.
[cited by applicant]
Ronning et al., “Molecular profiling of resident and infiltrating mononuclear phagocytes during rapid adult retinal degeneration using single-cell RNA sequencing,” Scientific Reports, Mar. 2019, 9(1):4858, 12 pages.
[cited by applicant]
Shi et al., “Optimization of Optomotor Response-based Visual Function Assessment in Mice,” Sci Rep., 2018, 8:9708, 10 pages.
[cited by applicant]
Short, “Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations,” Toxicol Pathol., Jan. 2008, 36(1):49-6.
[cited by applicant]
Stuart et al., “Comprehensive Integration of Single-Cell Data,” Cell, Jun. 2019, 177(7):1888-1902.e21, 37 pages.
[cited by applicant]
Tang et al., “Therapeutic Targeting of Retinal Immune Microenvironment With CSF-1 Receptor Antibody Promotes Visual Function Recovery After Ischemic Optic Neuropathy,” Front Immunol., Nov. 2020, 11:585918, 15 pages.
[cited by applicant]
Tian et al., “Current perspective of neuroprotection and glaucoma,” Clin Ophthalmol., Nov. 2015, 9:2109-18.
[cited by applicant]
Ugradar et al., “Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-IR expression,” Eye (Lond)., Sep. 2021, 35(9):2607-2612.
[cited by applicant]
Verhoeyen et al., “Reshaping human antibodies: grafting an antilysozyme activity,” Science, Mar. 1988, 239(4847):1534-6.
[cited by applicant]
Vijaya et al., “Prevalence and causes of low vision and blindness in an urban population: The Chennai Glaucoma Study,” Indian J Ophthalmol., Apr. 2014, 62(4):477-481.
[cited by applicant]
Wei et al., “Neuroglobin is an endogenous neuroprotectant for retinal ganglion cells against glaucomatous damage,” Am J Pathol., Dec. 2011, 179(6):2788-2797.
[cited by applicant]
Ambati et al., “Diffusion of high molecular weight compounds through sclera,” Invest. Ophthalmol. Vis. Sci., Apr. 2000, 41(5):1181-1185.
[cited by applicant]
Ambati et al., “Transscleral delivery of bioactive protein to the choroid and retina,” Invest. Ophthalmol. Vis. Sci., Apr. 2000, 41(5):1186-1191.
[cited by applicant]
Bell et al., “Does autoimmunity play a part in the pathogenesis of glaucoma?,” Prog. Retin. Eye Res., Sep. 2013, 36:199-216.
[cited by applicant]
Benny et al., “Continuous Delivery of Endogenous Inhibitors from Poly (Lactic-Co-Glycolic Acid) Polymeric Microspheres Inhibits Glioma Tumor Growth,” Clinical Cancer Research, Jan. 2005, 11(2):768-776.
[cited by applicant]
Bessero et al., “Neuroprotection for optic nerve disorders,” Curr. Opin. Neurol., 2010, 23(1):10-15.
[cited by applicant]
Blight, “Miracles and molecules—progress in spinal cord repair,” Nat. Neurosci., 2002, 5:1051-1054.
[cited by applicant]
Boughton, “Traumatic Optic Neuropathy: Previous Therapies Now Questioned or Shelved, ” EyeNet Magazine, 2009, retrieved on Jan. 10, 2019, retrieved from URL <https://www.aao.org/eyenet/article/traumatic-optic-neuropathy…
[cited by applicant]
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, 1990, 247:1306-1310.
[cited by applicant]
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single…
[cited by applicant]
Chen et al., “Commensal microflora-induced T cell responses mediate progressive neurodegeneration in glaucoma,” Nat Commun., Aug. 2018, 9(1):3209, 13 pages.
[cited by applicant]
Cho et al., “IGFBPL1 protects against the neuronal and vision loss in IGFBPL1-/- mice with ocular hypertension,” Abstract, Presented at 2019 ARVO Annual Meeting, Vancouver, B.C., Apr. 28-May 2, 2019; Investigative Ophth…
[cited by applicant]
Dahlmann-Noor et al., “Current approaches and future prospects for stem cell rescue and regeneration of the retina and optic nerve,” Can J. Ophthalmol., 2010, 45:333-341.
[cited by applicant]
Deumens et al., “Alignment of Glial Cells Stimulates Directional Neurite Growth of CNS Neurons In Vitro,” Neuroscience, 2004, 125(3):591-604.
[cited by applicant]
Dick et al., “Miniaturization in Glaucoma Monitoring and Treatment: A Review of New Technologies That Require a Minimal Surgical Approach,” Ophthalmol. Ther., 2019, 8:19-30.
[cited by applicant]
Doudet et al., “PET Imaging of Implanted Human Retinal Pigment Epithelial Cells in the MPTP-Induced Primate Model of Parkinson's Disease,” Experimental Neurology, Oct. 2004, 189(2):361-368.
[cited by applicant]
Dubois et al., “Research Criteria for the Diagnosis of Alzheimer's Disease: Revising the NINCDS-ADRDA Criteria,” The Lancet Neurology, Aug. 2007, 6(8):734-746.
[cited by applicant]
Fischer et al., “Drug Delivery to the Posterior Segment of the Eye, ” Eur J Ophthalmol., 2011, 21(Suppl 6):S20-26.
[cited by applicant]
Flammer et al., “What is the present pathogenetic concept of glaucomatous optic neuropathy?,” Surv Ophthalmol., Nov. 2007, 52(Suppl 2):S162-73.
[cited by applicant]
Gasco et al., “Microemulsions as topical delivery vehicles: Ocular administration of timolol,” J. Pharma Biomed Anal., 1989, 7(4):433-439.
[cited by applicant]
Gaudana et al., “Ocular Drug Delivery,” AAPS J., Sep. 2010, 12(3):348-360.
[cited by applicant]
GenBank Accession No. CAA24998.1, “Insulin-like Growth Factor 1A Precursor [
[cited by applicant]
GenBank Accession No. NM_001007563.2, “
[cited by applicant]
GenBank Accession No. NP_001007564.1, “Insulin-Like Growth Factor-Binding Protein-Like 1 Precursor [
[cited by applicant]
GenBank Accession No. NP_002147.2, “chaperonin [
[cited by applicant]
GenBank Accession No. WP_000729117.1, “MultiSpecies: chaperonin GroEL [Enterobacteriaceae],” dated Oct. 27, 2015, 1 page.
[cited by applicant]
GenBank Accession No. X00173.1, “
[cited by applicant]
Gonda et al., “Expression Profiles of Insulin-Like Growth Factor Binding Protein-Like 1 in the Developing Mouse Forebrain,” Gene Expr. Patterns, Feb. 2007, 7(4):431-440.
[cited by applicant]
Gramlich et al., “Enhanced Insight into the Autoimmune Component of Glaucoma: IgG Autoantibody Accumulation and Pro-Inflammatory Conditions in Human Glaucomatous Retina,” PLoS One, 2013, 8(2):e57557, 11 pages.
[cited by applicant]
Grotegut et al., “Abstract: Intravitreal HSP27 injection leads to retinal degeneration in rats,” Abstract, Presented at Proceedings of the ARVO Annual Meeting, Vancouver, CA, Apr. 28-May 2, 2019; Investigative Ophthalmo…
[cited by applicant]
Grus et al., “Autoimmunity and glaucoma,” J Glaucoma, Jan. 2008, 17(1):79-84.
[cited by applicant]
Guo et al., “A novel IGFBP like protein (IGFBPL-1) promotes axon outgrowth in retinal ganglion cells through the regulation of IGF-I signaling pathway,” Abstract, Presented at Association for Research in Vision and Opht…
[cited by applicant]
Guo et al., “Alzheimer's Disease and Retinal Neurodegeneration,” Curr. Alzheimer's Research, 2010, 7:3-14.
[cited by applicant]
Guo et al., “IGFBPL1 Regulates Axon Growth through IGF-1-mediated Signaling Cascades,” Sci Rep., Feb. 2018, 8(1):2054, 13 pages.
[cited by applicant]
Höke, “Mechanisms of Disease: what factors limit the success of peripheral nerve regeneration in humans?” Nat. Clin. Pract. Neurol., 2006, 2:448-454.
[cited by applicant]
Hope et al., “Generation of Multilamellar and Unilamellar Phospholipid Vesicles”, Chemistry and Physics of Lipids, Jun.-Jul. 1986, 40(2-4):89-107.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2012/026931, dated Sep. 12, 2013, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2020/020794, dated Sep. 16, 2021, 9 pages.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2012/026931, dated May 31, 2012, 6 pages.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2020/020794, dated Jun. 11, 2020, 11 pages.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2022/031615, mailed on Oct. 18, 2022, 11 pages.
[cited by applicant]
IrisVision.com [online], “Can Optic Nerve Damage be Treated?,” Aug. 6, 2020, retrieved on Aug. 27, 2022, retrieved from URL<irisvision.com/can-optic-nerve-damage-be-treated/>, 8 pages.
[cited by applicant]
Kubal, “Updated Imaging of Traumatic Brain Injury,” Radiologic Clinics of North America, 2012, 50(1):15-41.
[cited by applicant]
Lazorthes et al., “Advances in Drug Delivery Systems and Applications in Neurosurgery,” Advances and Technical Standards in Neurosurgery, 1991, 18:143-192.
[cited by applicant]
Losa et al., “Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol,” Pharmaceutical Research, Jan. 1993, 10(1):80-87.
[cited by applicant]
Margalit et al., “Retinal and Optic Nerve Diseases, ” Artificial Organs, 2003, 27:963-974.
[cited by applicant]
My.ClevelandClinic.org [online], “Leber Hereditary Optic Neuropathy (Sudden Vision Loss),” Feb. 26, 2021, retrieved on Aug. 27, 2022, retrieved from URL<my.clevelandclinic.org/health/diseases/15620-leber-hereditary-opti…
[cited by applicant]
Nei.Nih.gov [online], “Glaucoma,” Apr. 21, 2022, retrieved on Aug. 27, 2022, retrieved from URL<www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/glaucoma>, 6 pages.
[cited by applicant]
Novak et al., “Huntington's Disease: Clinical Presentation and Treatment,” International Review of Neurobiology, 2011, 98:297-323.
[cited by applicant]
Novikova et al., “Biopolymers and Biodegradable Smart Implants for Tissue Regeneration After Spinal Cord Injury,” Current Opinion in Neurology, Dec. 2003, 6(6):711-715.
[cited by applicant]
Ommaya, “Implantable Devices for Chronic Access and Drug Delivery to the Central Nervous System,” Cancer Drug Delivery, 1984, 1(2):169-179.
[cited by applicant]
Pan et al., “A role for Insulin-like growth factor binding protein-like protein 1 in Microglia,” Abstract, Presented at 2019 ARVO Annual Meeting, Vancouver, B.C., Apr. 28-May 2, 2019; Investigative Ophthalmology & Visua…
[cited by applicant]
Pawson et al., “Assembly of Cell Regulatory Systems Through Protein Interaction Domains,” Science, 2003, 300:445-452.
[cited by applicant]
Peragallo et al., “Is there treatment for Leber Hereditary Optic Neuropathy?,” Curr. Opin. Ophthalmol., 2015, 26:450-457.
[cited by applicant]
Quigley et al., “The number of people with glaucoma worldwide in 2010 and 2020,” Br J Ophthalmol., Mar. 2006, 90(3):262-7.
[cited by applicant]
Schmidt et al., “Neural Tissue Engineering: Strategies for Repair and Regeneration,” Annu. Rev. Biomed. Eng., 2003, 5:293-347.
[cited by applicant]
Sherman et al., “Management of Traumatic Optic Neuropathy With Coexistent Spinal Cord Injury: A Case Report,” Arch Phys Med Rehabil., 1997, 78(9):1012-1014.
[cited by applicant]
Szoka et al., “Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes),” Annual Review of Biophysics and Bioengineering, 1980, 9:467-508.
[cited by applicant]
Tan et al., “Simulation of Intratumoral Release of Etanidazole: Effects of the Size of Surgical Opening,” Journal of Pharmaceutical Sciences, Apr. 2003, 92(4):773-789.
[cited by applicant]
Tangri and Khurana, “Basics of ocular drug delivery systems,” Intl J Res Pharma Biomed Sci., Jan. 2011, 2(4): 1541-1552.
[cited by applicant]
Tarride et al., “New Glaucoma Diagnostic Technologies: A Systematic Review of Economic Studies,” Canadian Journal of Ophthalmology, Feb. 2011, 46(1):89-91.
[cited by applicant]
Tezel et al., “The Immune System and Glaucoma,” Current Opinion in Ophthalmology, Apr. 2004, 15(2):80-84.
[cited by applicant]
't Hart et al., “The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system,” Curr. Opin. Neurol., 2003, 16:375-383.
[cited by applicant]
Thee et al., “Immune tolerance to HSP60 attenuates neurodegeneration in a mouse model of glaucoma,” Abstract, Presented at 2018 ARVO Annual Meeting, Honolulu, HI, Apr. 29-May 3, 2018; Investigative Ophthalmology & Visua…
[cited by applicant]
Tóth et al., “Overexpression of Hsp27 ameliorates symptoms of Alzheimer's disease in APP/PS1 mice,” Cell Stress Chaperones, Nov. 2013, 18(6):759-71.
[cited by applicant]
Vu et al., “The Immunology of Glaucoma,” Asia Pacific J. Ophthalmol., 2012, 1(5):303-311.
[cited by applicant]
Walland et al., “Failure of medical therapy despite normal intraocular pressure,” Clin Exp Ophthalmol., Dec. 2006, 34(9):827-36.
[cited by applicant]
Wax, “The case for autoimmunity in glaucoma,” Exp. Eye Res., Aug. 2011, 93(2):187-190.
[cited by applicant]
Wei et al., “Abstract: A neuroprotective role of IGFBPL1 in glaucoma,” Abstract, Presented at Proceedings of the ARVO Annual Meeting, Honolulu, HI, Apr. 29-May 3, 2018; Investigative Ophthalmology and Visual Science, Ju…
[cited by applicant]
O'Reilly et al., “HspB1 (Hsp27) Expression and Neuroprotection in the Retina,” Mol. Neurobiol., 2010, 42:124-132.
[cited by applicant]
Johnson et al., “Rodent models of glaucoma,” HHS Public Access Author Manuscript, doi: 10.1016/j.brainresbull.2009.04.004, published online Feb. 15, 2011; published in final edited form as: Brain Res Bull., Feb. 2010, 8…
[cited by applicant]